Par Capital Management Inc decreased Mgm Resorts International (MGM) stake by 33.75% reported in 2018Q1 SEC filing. Par Capital Management Inc sold 1.00M shares as Mgm Resorts International (MGM)’s stock declined 10.98%. The Par Capital Management Inc holds 1.96 million shares with $68.73M value, down from 2.96 million last quarter. Mgm Resorts International now has $17.09 billion valuation. The stock decreased 1.98% or $0.62 during the last trading session, reaching $30.7. About 1.90M shares traded. MGM Resorts International (NYSE:MGM) has declined 0.47% since June 19, 2017 and is downtrending. It has underperformed by 13.04% the S&P500. Some Historical MGM News: ; 15/05/2018 – OMEGA ADVISORS DISSOLVES STAKE IN MGM RESORTS INTERNATIONAL – SEC FILING; 08/05/2018 – MGM’s Murren Says ‘Investors Don’t Care Enough’ About Diversity (Video); 05/04/2018 – New York Post: MGM Resorts may roll the dice and buy Wynn Resorts; 14/05/2018 – BREAKING: US Supreme Court rules for New Jersey in state’s fight to legalize sports betting; $CZR, $MGM jumping following the news; 19/04/2018 – MGM RESORTS INTERNATIONAL MGM.N : NOMURA RAISES TARGET PRICE TO $42 FROM $41; 17/04/2018 – Hartford Courant: Possible MGM Bid For Wynn Boston Casino Raises Questions About Springfield; 08/05/2018 – BNN: MGM Chief Executive Rips `Hypocritical’ Investors on Diversity; 26/04/2018 – MGM Resorts Cash Balance at March 31 Was $1.5 Billion; 06/04/2018 – Other sources told the Post that MGM still has time to change its mind and that no official talks have occurred; 29/03/2018 – MGM Resorts International Commemorates 50th Anniversary of Dr. Martin Luther King Jr.’s Assassination with Donation to National Civil Rights Museum
The stock of Jounce Therapeutics, Inc. (NASDAQ:JNCE) is a huge mover today! The stock increased 6.18% or $0.49 during the last trading session, reaching $8.42. About 542,261 shares traded. Jounce Therapeutics, Inc. (NASDAQ:JNCE) has declined 49.76% since June 19, 2017 and is downtrending. It has underperformed by 62.33% the S&P500. Some Historical JNCE News: ; 09/04/2018 – STAT Plus: With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies; 30/04/2018 – Merck: FDA Grants Priority Review to sBLA for Keytruda Combination; 17/05/2018 – Jounce Therapeutics Presenting at Conference Jun 5; 28/03/2018 – lmmunovaccine Announces Initiation of Patient Dosing in lnvestigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL; 25/05/2018 – Oncolytics Biotech® Announces Research Collaboration with the Keck School of Medicine of USC Combining REOLYSIN® with Keytruda®, Velcade® and Dexamethasone; 08/03/2018 – REG-Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer; 25/03/2018 – ONO: OPDIVO APPROVED FOR WIDER USE IN HODGKIN LYMPHOMA IN KOREA; 28/03/2018 – IMMUNOVACCINE ANNOUNCES INITIATION OF PATIENT DOSING IN INVESTIGATOR-SPONSORED PHASE 2 CLINICAL TRIAL OF ITS LEAD CANDIDATE DPX-SURVIVAC USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH DLBCL; 19/05/2018 – #2 UPDATED: The top winners and losers on ASCO abstract night: Loxo, Blueprint, Jounce, Merck KGaA and more; 09/05/2018 – JOUNCE THERAPEUTICS SEES CASH FUNDING OPS AT LEAST NEXT 24 MOSThe move comes after 6 months positive chart setup for the $273.51 million company. It was reported on Jun, 19 by Barchart.com. We have $8.84 PT which if reached, will make NASDAQ:JNCE worth $13.68M more.
Par Capital Management Inc increased Owens Corning New (NYSE:OC) stake by 20,215 shares to 1.96M valued at $157.68M in 2018Q1. It also upped Stars Group Inc stake by 720,311 shares and now owns 841,400 shares. Controladora Vuela Cia De Av (NYSE:VLRS) was raised too.
Among 18 analysts covering MGM Resorts (NYSE:MGM), 14 have Buy rating, 0 Sell and 4 Hold. Therefore 78% are positive. MGM Resorts had 67 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Nomura with “Buy” on Wednesday, November 1. The company was maintained on Monday, May 7 by Jefferies. Telsey Advisory Group maintained MGM Resorts International (NYSE:MGM) on Friday, June 17 with “Outperform” rating. The company was maintained on Friday, October 30 by Deutsche Bank. The rating was maintained by Nomura with “Buy” on Wednesday, October 5. The firm has “Overweight” rating by Morgan Stanley given on Friday, October 13. The firm has “Hold” rating by Zacks given on Wednesday, August 5. The stock of MGM Resorts International (NYSE:MGM) earned “Outperform” rating by Telsey Advisory Group on Friday, December 9. On Friday, May 6 the stock rating was maintained by Telsey Advisory Group with “Outperform”. The rating was maintained by Deutsche Bank with “Hold” on Friday, April 27.
More notable recent MGM Resorts International (NYSE:MGM) news were published by: Seekingalpha.com which released: “Has MGM Lost Its Way… Again?” on May 31, 2018, also Fool.com with their article: “Sports Betting Legalization Gets MGM Resorts to Reconsider Expansion” published on June 07, 2018, Prnewswire.com published: “IGT Powering Retail Sports Betting at MGM Resorts International’s Borgata Hotel Casino & Spa as Legalized Sports …” on June 14, 2018. More interesting news about MGM Resorts International (NYSE:MGM) were released by: Seekingalpha.com and their article: “Dr. J places first bet at MGM’s Borgata” published on June 15, 2018 as well as Seekingalpha.com‘s news article titled: “MGM Resorts plants a flag near NYC” with publication date: May 30, 2018.
Since February 22, 2018, it had 1 insider purchase, and 9 sales for $5.42 million activity. Shares for $1.26 million were sold by D’ARRIGO DANIEL. The insider HERMAN ALEXIS sold 3,840 shares worth $121,551. The insider HORNBUCKLE WILLIAM sold 60,000 shares worth $2.18 million. Another trade for 1,585 shares valued at $49,045 was sold by GAY MARY CHRISTINE. The insider TAYLOR DANIEL J sold $434,632. The insider BIBLE WILLIAM A sold $215,773. Another trade for 5,624 shares valued at $179,330 was sold by Mckinney-James Rose.
Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.06, from 0.95 in 2017Q4. It is negative, as 54 investors sold MGM shares while 147 reduced holdings. 57 funds opened positions while 121 raised stakes. 443.98 million shares or 1.45% less from 450.52 million shares in 2017Q4 were reported. Mitsubishi Ufj Trust & Corp holds 919,189 shares or 0.06% of its portfolio. Soroban Capital Partners Limited Partnership has 21.97 million shares for 4.39% of their portfolio. Cwh Mngmt reported 117,472 shares stake. Cap Ltd Ca holds 0.25% in MGM Resorts International (NYSE:MGM) or 39,909 shares. Creative Planning accumulated 73,400 shares. Swiss Savings Bank holds 1.45 million shares or 0.06% of its portfolio. Iridian Asset Mgmt Ltd Liability Com Ct accumulated 4.80M shares. Frontier Ltd Liability Corporation holds 0.43% of its portfolio in MGM Resorts International (NYSE:MGM) for 1.70M shares. National Pension Ser holds 0.09% of its portfolio in MGM Resorts International (NYSE:MGM) for 509,202 shares. Management Associates holds 21,400 shares or 1.15% of its portfolio. Morgan Stanley, New York-based fund reported 3.61M shares. Retirement Sys Of Alabama holds 243,508 shares or 0.04% of its portfolio. Braun Stacey accumulated 1.12% or 466,617 shares. The North Carolina-based Bank Of America Corp De has invested 0.03% in MGM Resorts International (NYSE:MGM). Principal Fincl Grp has invested 0.03% in MGM Resorts International (NYSE:MGM).
Analysts await MGM Resorts International (NYSE:MGM) to report earnings on July, 26. They expect $0.27 EPS, down 12.90% or $0.04 from last year’s $0.31 per share. MGM’s profit will be $150.33 million for 28.43 P/E if the $0.27 EPS becomes a reality. After $0.34 actual EPS reported by MGM Resorts International for the previous quarter, Wall Street now forecasts -20.59% negative EPS growth.
Analysts await Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report earnings on August, 8. They expect $-0.38 earnings per share, down 245.45% or $0.27 from last year’s $-0.11 per share. After $-0.40 actual earnings per share reported by Jounce Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -5.00% EPS growth.
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $273.51 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.
More notable recent Jounce Therapeutics, Inc. (NASDAQ:JNCE) news were published by: Seekingalpha.com which released: “Jounce: Sifting Through The Wreckage” on June 04, 2018, also Nasdaq.com with their article: “Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason” published on June 05, 2018, Nasdaq.com published: “Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients …” on June 02, 2018. More interesting news about Jounce Therapeutics, Inc. (NASDAQ:JNCE) were released by: Globenewswire.com and their article: “Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic …” published on June 06, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 06/04: (VSAR) (VYGR) (GHDX) Higher; (NKTR) (JNCE) (CFX) Lower (more…)” with publication date: June 04, 2018.